Clinical Data and Effects of BMP-2 on the Patients' Samples
| Patient . | Age/Sex . | M Isotype . | Clinical Stage* . | Source of Samples . | % Myeloma Cells . | Patients' Treatment . | % Inhibition by BMP-2† . |
|---|---|---|---|---|---|---|---|
| 1 | 56/F | BJPλ | III A | BM | 79 | — | 63 |
| 2 | 67/M | IgGλ | III A | BM | 34 | MP | 77 |
| 3 | 65/F | IgAλ | III B | PE | 100 | VAD | 76 |
| 4 | 57/M | IgAλ | III A | BM | 39 | MP | 83 |
| 5 | 37/M | IgGλ | III A | BM | 65 | — | 81 |
| 6 | 55/F | IgAλ | III A | BM | 56 | MP | 87 |
| Patient . | Age/Sex . | M Isotype . | Clinical Stage* . | Source of Samples . | % Myeloma Cells . | Patients' Treatment . | % Inhibition by BMP-2† . |
|---|---|---|---|---|---|---|---|
| 1 | 56/F | BJPλ | III A | BM | 79 | — | 63 |
| 2 | 67/M | IgGλ | III A | BM | 34 | MP | 77 |
| 3 | 65/F | IgAλ | III B | PE | 100 | VAD | 76 |
| 4 | 57/M | IgAλ | III A | BM | 39 | MP | 83 |
| 5 | 37/M | IgGλ | III A | BM | 65 | — | 81 |
| 6 | 55/F | IgAλ | III A | BM | 56 | MP | 87 |
Ig indicates immunoglobulin; BM, bone marrow; PE, pleural effusion; MP, melphalan + prednisolone; VAD, vincristine + doxorubicin hydrochloride (ADR) + dexamethazone; M, M-protein; BJP, Bence Jones protein.
According to the Durie Salmon staging.
Mononuclear cells from patients were cultured for 48 hours with BMP-2 (50 ng/mL). Inhibition of cell growth was measured by MTT assay and expressed as percentage of inhibition of cellular proliferation compared with cells without treatment of BMP-2.